Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Illumina Inc's Business Segments
Illumina Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2026
Reportable Segments
1
Largest Segment
Core Illumina
Total Revenue
$ 1,159
Regions Reported
2
Revenue Share by Reportable Segment - Q2 FY2026
- Core Illumina100%
Revenue by Reportable Segment - Q2 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Core Illumina | $ 1,159 | 100% |
Revenue Share by Region - Q2 FY2026
- EMEA31.8%
- Asia Pacific7.1%
Revenue by Geographic Region - Q2 FY2026
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| EMEA | $ 368 | 31.8% |
| Asia Pacific | $ 82 | 7.1% |
Revenue by Product & Service Category - Q2 FY2026
- Product84.7%
- Consumables66.9%
- Service15.3%
- Instruments10.8%
Revenue by Product & Service Category - Q2 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 982 | 84.7% |
| Consumables | $ 775 | 66.9% |
| Service | $ 177 | 15.3% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Illumina Inc dataset.
Description of Illumina Inc
Business Description of Illumina Inc.
Illumina Inc. is a prominent American biotechnology company that operates at the forefront of genetic analysis, specializing in the development and production of next-generation sequencing (NGS) platforms, software, and consumables. Established in 1998 and headquartered in San Diego, California, Illumina has continually positioned itself as a pioneer in genomic technology, revolutionizing the ways in which researchers and clinicians understand and utilize genetic information.
The company’s flagship product, the Genome Analyzer, set new standards for high-throughput DNA sequencing, enabling researchers to map genomes, identify genetic variations, and explore complex disease pathways with unprecedented efficiency and accuracy. Illuminas sequencing systems leverage proprietary chemistry and advanced data analysis software, facilitating the generation of high-fidelity genomic data that supports a wide array of scientific investigations.
Illuminas product portfolio extends beyond sequencing instruments to include a variety of genetic analysis tools, such as microarrays, PCR (polymerase chain reaction) kits, and robust software platforms for data interpretation. These products are integral to a multitude of research and clinical applications across several fields, including healthcare, personalized medicine, agriculture, and environmental science. In healthcare, Illuminas technologies are instrumental in oncology, enabling the development of targeted therapies, as well as in prenatal screening and rare genetic disorder diagnostics.
The company collaborates with leading pharmaceutical and biotechnology firms, as well as academic research institutions, to support the discovery and development of new therapeutics and innovative solutions for challenging diseases, including cancer, diabetes, and various genetic disorders. These partnerships leverage Illuminas advanced sequencing capabilities to accelerate research timelines and improve patient outcomes.
Illumina places a strong emphasis on innovation and continuous improvement in its technological offerings. This commitment is evident in the companys investment in research and development, aimed at enhancing existing products and introducing novel tools that cater to the evolving needs of researchers and clinicians. Illumina has also been a key participant in several transformative global scientific initiatives, including the UK’s 100,000 Genomes Project and the US All of Us Research Program, both of which aim to advance the understanding of genomics in public health.
In addition to its sequencing offerings and external collaborations, Illumina provides comprehensive services that include sequencing and data analysis for a range of applications, both in research settings and clinical diagnostics. Through these services, Illumina empowers researchers and healthcare providers to harness genomic data effectively, driving forward insights that can lead to more personalized and effective medical interventions.
Overall, Illumina Inc. stands as a leader in the genetic analysis industry, continuously pushing the boundaries of science and technology. Its commitment to innovation, collaboration, and quality reassures its position as a pivotal force in the ongoing quest to decode the complexities of the genome, ultimately enhancing our understanding of biology and improving health outcomes around the world.
Illumina Inc. is a prominent American biotechnology company that operates at the forefront of genetic analysis, specializing in the development and production of next-generation sequencing (NGS) platforms, software, and consumables. Established in 1998 and headquartered in San Diego, California, Illumina has continually positioned itself as a pioneer in genomic technology, revolutionizing the ways in which researchers and clinicians understand and utilize genetic information.
The company’s flagship product, the Genome Analyzer, set new standards for high-throughput DNA sequencing, enabling researchers to map genomes, identify genetic variations, and explore complex disease pathways with unprecedented efficiency and accuracy. Illuminas sequencing systems leverage proprietary chemistry and advanced data analysis software, facilitating the generation of high-fidelity genomic data that supports a wide array of scientific investigations.
Illuminas product portfolio extends beyond sequencing instruments to include a variety of genetic analysis tools, such as microarrays, PCR (polymerase chain reaction) kits, and robust software platforms for data interpretation. These products are integral to a multitude of research and clinical applications across several fields, including healthcare, personalized medicine, agriculture, and environmental science. In healthcare, Illuminas technologies are instrumental in oncology, enabling the development of targeted therapies, as well as in prenatal screening and rare genetic disorder diagnostics.
The company collaborates with leading pharmaceutical and biotechnology firms, as well as academic research institutions, to support the discovery and development of new therapeutics and innovative solutions for challenging diseases, including cancer, diabetes, and various genetic disorders. These partnerships leverage Illuminas advanced sequencing capabilities to accelerate research timelines and improve patient outcomes.
Illumina places a strong emphasis on innovation and continuous improvement in its technological offerings. This commitment is evident in the companys investment in research and development, aimed at enhancing existing products and introducing novel tools that cater to the evolving needs of researchers and clinicians. Illumina has also been a key participant in several transformative global scientific initiatives, including the UK’s 100,000 Genomes Project and the US All of Us Research Program, both of which aim to advance the understanding of genomics in public health.
In addition to its sequencing offerings and external collaborations, Illumina provides comprehensive services that include sequencing and data analysis for a range of applications, both in research settings and clinical diagnostics. Through these services, Illumina empowers researchers and healthcare providers to harness genomic data effectively, driving forward insights that can lead to more personalized and effective medical interventions.
Overall, Illumina Inc. stands as a leader in the genetic analysis industry, continuously pushing the boundaries of science and technology. Its commitment to innovation, collaboration, and quality reassures its position as a pivotal force in the ongoing quest to decode the complexities of the genome, ultimately enhancing our understanding of biology and improving health outcomes around the world.
Illumina Inc. is a leading company in the field of genomic sequencing, recognized for its innovative solutions that cater to a variety of segments, including research, clinical applications, and applied genomics. The companys extensive offerings are categorized into distinct segments, products, and services designed to meet the diverse needs of scientists, healthcare providers, and industry professionals.
Segments
1. Genomic Sequencing
- Illumina is a pioneer in genomic sequencing, providing advanced technologies that facilitate in-depth analysis of DNA and RNA. These solutions empower researchers to conduct a wide array of genetic studies, exploring genes, variations, and gene expression with exceptional resolution and scale. The platforms are versatile, accommodating various research applications ranging from fundamental biological research to complex genomic and transcriptomic studies.
2. Clinical Genomics
- In clinical applications, Illumina’s genomic sequencing tools are crucial for diagnosing and managing genetic disorders. Their technologies enable healthcare professionals to identify genetic mutations linked to various diseases, significantly advancing the field of personalized medicine. Clinical genomics products include hereditary cancer panels, pharmacogenomic tests, and tools for diagnosing rare genetic diseases, allowing for tailored therapies and personalized treatment plans based on individual genetic information.
3. Applied Genomics
- Illumina also applies its genomic expertise to various industries such as agriculture, environmental science, and forensics. In agriculture, its technologies are used to enhance crop resilience and productivity through genomic selection, which fosters yield improvement. In environmental science, Illumina’s sequencing tools help monitor biodiversity and assess ecological changes. In the realm of forensics, these technologies assist in criminal investigations and the genetic analysis of biological evidence, contributing to public safety and justice.
Products
1. NovaSeq Series
- The flagship series of high-throughput sequencing platforms, NovaSeq systems are designed for maximum scalability and versatility in genomic research. Capable of sequencing millions of DNA fragments simultaneously, these systems are ideal for applications such as population genomics and large-scale clinical studies. The NovaSeq offers high accuracy and cost-efficiency, making it suitable for both academic and commercial uses.
2. NextSeq Series
- The NextSeq series provides a compact, mid-throughput sequencing option that delivers reliable results for diverse applications, including gene expression analysis, somatic variant detection, and targeted resequencing. Its accessibility and user-friendly design make it an attractive choice for laboratories aiming for high-quality sequencing without significant investment.
3. MiSeq Series
- The MiSeq is a benchtop sequencer tailored for smaller-scale sequencing tasks. Known for its rapid turnaround and high accuracy, it serves applications such as microbial genomics, amplicon sequencing, and targeted resequencing. The MiSeq’s streamlined workflow and multiplexing capabilities make it a preferred choice for researchers requiring quick and reliable results.
4. HiSeq Series
- Optimized for high-throughput sequencing, the HiSeq series is designed for large genomic projects, including whole-genome sequencing and transcriptomics studies. With impressive data output and quality, HiSeq systems enable researchers to tackle complex projects that demand large amounts of sequencing data.
5. DNA Library Preparation
- Illumina provides a variety of DNA library preparation kits, including the TruSeq and Nextera series. These products ensure efficient and high-quality library construction, streamlining the workflow necessary for preparing samples for downstream sequencing applications.
Services
1. Genomic Sequencing Services
- Illumina offers a range of genomic sequencing services tailored for both research and clinical settings. This includes whole-genome sequencing, targeted exome sequencing, RNA sequencing, and custom panel design. These services allow clients to leverage Illumina’s technological infrastructure and expertise to obtain high-quality genomic data without needing to invest in in-house sequencing capabilities.
2. Bioinformatics Services
- To support the management and analysis of complex sequencing data, Illumina provides comprehensive bioinformatics services. These services include data management, quality control, variant calling, and biological interpretation of sequencing results. By employing advanced computational methodologies, Illumina aids researchers in deriving meaningful insights from their genomic data, thereby facilitating greater discoveries and innovations in the field.
3. Training and Support
- Illumina emphasizes the importance of training and customer support. The company offers various educational resources, including on-site workshops, online training modules, and technical assistance. This commitment to education ensures that researchers and clinicians fully utilize Illumina’s products and solutions, maximizing the impact of their genomic research and clinical applications.
Summary
Illumina’s extensive suite of genomic sequencing technologies, products, and services solidifies its leadership position in the genomics industry. By equipping researchers and healthcare providers with essential tools to comprehensively explore genetic information, Illumina is paving the way for significant advancements in genomics, personalized medicine, and applied sciences across diverse fields.
Segments
1. Genomic Sequencing
- Illumina is a pioneer in genomic sequencing, providing advanced technologies that facilitate in-depth analysis of DNA and RNA. These solutions empower researchers to conduct a wide array of genetic studies, exploring genes, variations, and gene expression with exceptional resolution and scale. The platforms are versatile, accommodating various research applications ranging from fundamental biological research to complex genomic and transcriptomic studies.
2. Clinical Genomics
- In clinical applications, Illumina’s genomic sequencing tools are crucial for diagnosing and managing genetic disorders. Their technologies enable healthcare professionals to identify genetic mutations linked to various diseases, significantly advancing the field of personalized medicine. Clinical genomics products include hereditary cancer panels, pharmacogenomic tests, and tools for diagnosing rare genetic diseases, allowing for tailored therapies and personalized treatment plans based on individual genetic information.
3. Applied Genomics
- Illumina also applies its genomic expertise to various industries such as agriculture, environmental science, and forensics. In agriculture, its technologies are used to enhance crop resilience and productivity through genomic selection, which fosters yield improvement. In environmental science, Illumina’s sequencing tools help monitor biodiversity and assess ecological changes. In the realm of forensics, these technologies assist in criminal investigations and the genetic analysis of biological evidence, contributing to public safety and justice.
Products
1. NovaSeq Series
- The flagship series of high-throughput sequencing platforms, NovaSeq systems are designed for maximum scalability and versatility in genomic research. Capable of sequencing millions of DNA fragments simultaneously, these systems are ideal for applications such as population genomics and large-scale clinical studies. The NovaSeq offers high accuracy and cost-efficiency, making it suitable for both academic and commercial uses.
2. NextSeq Series
- The NextSeq series provides a compact, mid-throughput sequencing option that delivers reliable results for diverse applications, including gene expression analysis, somatic variant detection, and targeted resequencing. Its accessibility and user-friendly design make it an attractive choice for laboratories aiming for high-quality sequencing without significant investment.
3. MiSeq Series
- The MiSeq is a benchtop sequencer tailored for smaller-scale sequencing tasks. Known for its rapid turnaround and high accuracy, it serves applications such as microbial genomics, amplicon sequencing, and targeted resequencing. The MiSeq’s streamlined workflow and multiplexing capabilities make it a preferred choice for researchers requiring quick and reliable results.
4. HiSeq Series
- Optimized for high-throughput sequencing, the HiSeq series is designed for large genomic projects, including whole-genome sequencing and transcriptomics studies. With impressive data output and quality, HiSeq systems enable researchers to tackle complex projects that demand large amounts of sequencing data.
5. DNA Library Preparation
- Illumina provides a variety of DNA library preparation kits, including the TruSeq and Nextera series. These products ensure efficient and high-quality library construction, streamlining the workflow necessary for preparing samples for downstream sequencing applications.
Services
1. Genomic Sequencing Services
- Illumina offers a range of genomic sequencing services tailored for both research and clinical settings. This includes whole-genome sequencing, targeted exome sequencing, RNA sequencing, and custom panel design. These services allow clients to leverage Illumina’s technological infrastructure and expertise to obtain high-quality genomic data without needing to invest in in-house sequencing capabilities.
2. Bioinformatics Services
- To support the management and analysis of complex sequencing data, Illumina provides comprehensive bioinformatics services. These services include data management, quality control, variant calling, and biological interpretation of sequencing results. By employing advanced computational methodologies, Illumina aids researchers in deriving meaningful insights from their genomic data, thereby facilitating greater discoveries and innovations in the field.
3. Training and Support
- Illumina emphasizes the importance of training and customer support. The company offers various educational resources, including on-site workshops, online training modules, and technical assistance. This commitment to education ensures that researchers and clinicians fully utilize Illumina’s products and solutions, maximizing the impact of their genomic research and clinical applications.
Summary
Illumina’s extensive suite of genomic sequencing technologies, products, and services solidifies its leadership position in the genomics industry. By equipping researchers and healthcare providers with essential tools to comprehensively explore genetic information, Illumina is paving the way for significant advancements in genomics, personalized medicine, and applied sciences across diverse fields.